DrMKZ

I am saluting to GSK today. Belumimab a new class of, a fully human monoclonal antibody that inhibit the B- lymphocytes stimulator ( BlyS).

A new and approved class of drugs in the U.S for the treatment of Systemic Lupus Erythmatosis.  BLyS plays a key role in B lymphocyte differentiation, survival and activation.

Mechanism of action as proposed in the BENLYSTA website

Belimumab blocks the binding of soluble BLyS, a B-cell survival factor, to its receptors on B cells. Belimumab does not bind B cells directly, but by binding BLyS, belimumab inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. BLyS is a naturally occurring protein which was discovered by HGS in 1996.

Now I know why i learn Immunology and Haematology!

Still have to read on abiximab, rituximab and omalizumab!!